The formulation came from a GMP-certified supplier in Uttarakhand, India, and was extracted at the All India Institute of Ayurveda in New Delhi with a 70:30 ethanol–water mixture. Investigators macerated a 25-gram sample for eight hours with stirring at 300 rpm and then for 16 additional hours without stirring. Following filtration through Whatman No. 42 paper and a 0.22-micrometer PTFE membrane, the extract was concentrated by rotary evaporation at 40 °C under reduced pressure and stored at −20 °C in amber vials. For chemical analysis, the extract was separated on a C18 UHPLC column during a 30-minute gradient run at 0.3 milliliters per minute. High-resolution mass spectra were acquired in positive and negative electrospray ionization modes, with data-dependent top-five MS2 fragmentation. Peak detection, centroiding and chromatogram alignment were followed by mass-error screening at no more than 5 ppm, retention-time alignment within 0.2–0.3 minutes and quality-control checks. The analysis tentatively identified 109 compounds in negative mode and 259 in positive mode. Some assignments met Level 2 MSI criteria, based on spectral and retention-time matches, while confirmation with reference standards enabled Level 1 identification.

The detected compounds entered an in silico screening pipeline intended to prioritize constituents that might plausibly reach the brain. SwissADME and Molsoft were used to examine absorption, distribution, metabolism, excretion, toxicity, Lipinski’s Rule of Five and blood–brain barrier status. Canonical chemical structures obtained from PubChem were submitted to SwissTargetPrediction, with predicted targets retained when their probability was at least 0.10. Separately, the team collected mild-cognitive-impairment genes from NCBI Gene and GeneCards, applying a relevance threshold of at least 10 to GeneCards entries. After duplicate entries were removed, the analysis contained 1,204 predicted compound targets and 16,035 disease-associated genes. Their intersection produced 942 shared genes, which were carried into protein-interaction and functional analyses. These filters and intersections were computational prioritization steps, not measurements of blood concentrations, brain exposure or target modulation.

Cytoscape, STRING and CytoHubba analyses ranked AKT1, TP53, TNF, SRC, IL6, EGFR, CTNNB1, STAT3, ESR1, HSP90AA1, CASP3, JUN, BCL2, HIF1A and PPARG among the leading network genes. Gene Ontology enrichment linked the network with protein and enzyme binding, transcriptional regulation, apoptosis, inflammatory responses, oxidative-stress signaling and synaptic transmission. KEGG results included Alzheimer’s disease, PI3K–AKT, MAPK, TNF, apoptosis, HIF-1, estrogen and Wnt/β-catenin signaling, along with IL-17, NOD-like receptor and C-type lectin receptor signaling. The network consequently associated the formulation with several mechanisms relevant to MCI, including inflammation, cell survival, metabolism and programmed cell death. It also showed overlap with pathways marked in the paper for Alzheimer’s, Huntington’s and amyotrophic lateral sclerosis, but the analysis does not demonstrate that any of these genes changes in an individual with MCI.

Molecular docking prioritized AKT1 with isoferulic acid, PPARG with arctigenin and TNF with 3,6,2′-trimethoxyflavone. Their respective predicted scores were −8.010, −7.647 and −7.891 kilocalories per mole. Hydrogen bonds, hydrophobic contacts and π–π interactions supported the selected poses. Isoferulic acid was predicted to interact with AKT1 residues including GLN61, TYR151, TYR59, TYR119, SER60 and LEU57. Arctigenin formed hydrogen bonds with HIE449, TYR473 and SER289 in PPARG, while the TNF–trimethoxyflavone model showed polar and hydrophobic contacts involving residues such as GLN61, TYR151 and TYR59. Donepezil and lecanemab were docked under the same reported conditions, receiving scores of −5.635 and −6.121 kilocalories per mole, respectively. The numerical comparison favored the three selected plant compounds, but the authors cautioned that docking scores alone do not predict biological efficacy or clinical performance. Exact receptor-grid coordinates and dimensions were not retained in the available records, and no retrospective redocking or ligand-pose RMSD validation was performed.

Density functional theory calculations examined the electronic properties of isoferulic acid, arctigenin and 3,6,2′-trimethoxyflavone using Gaussian 16. Their structures were optimized with the B3LYP hybrid functional and 6-31G(d,p) basis set, with solvent effects treated using the IEFPCM model; frequency analyses indicated that the optimized structures had no imaginary frequencies. Isoferulic acid had an ionization potential of 5.68 electron volts, an energy gap of 4.13 electron volts and an electrophilicity index of 3.16 electron volts. The trimethoxyflavone had a similar 4.27-electron-volt gap and the highest reported electrophilicity value, 3.27 electron volts. Arctigenin differed sharply, with an 8.45-electron-volt ionization potential, a 12.01-electron-volt gap and an electrophilicity index of 0.50 electron volts. These calculations characterize predicted electronic reactivity and chemical stability; they do not measure binding, metabolism or biological activity in cells or animals. The documented protocol did not specify a nondefault self-consistent-field setting or apply a separate empirical dispersion correction.

Each selected complex was then examined in one 500-nanosecond molecular dynamics trajectory in Schrödinger Maestro. The systems were solvated with TIP3P water, surrounded by a 10-ångström buffer and neutralized with sodium ions; the simulations used a constant-particle-number, constant-pressure and constant-temperature ensemble at 300 K. No independent replicate simulations were performed. The TNF complex showed backbone root-mean-square deviations of approximately 1.2 to 3.2 ångströms, while PPARG remained between about 1.0 and 3.0 ångströms. AKT1 was more flexible, reaching approximately 4.0 ångströms, which the authors interpreted as conformational variation rather than outright destabilization. Ligand motions followed the corresponding protein motions in all three systems, supporting continued retention near the predicted binding regions. Residues associated with the predicted binding interfaces showed lower fluctuations than peripheral loops and terminal regions. Hydrogen bonds, hydrophobic contacts and water bridges persisted over substantial portions of the trajectories, while radius of gyration and solvent-accessible surface area remained comparatively stable.

Post-simulation analysis used backbone alignment, principal component analysis and molecular mechanics with generalized Born surface area calculations. The AKT1 and PPARG systems formed relatively compact principal-component trajectories, while TNF showed a more elongated distribution that nevertheless retained endpoint clustering. Free-energy landscapes differed among the complexes: PPARG had the widest and deepest reported low-energy basin, whereas AKT1 and TNF explored more elevated conformations. MM-GBSA estimated mean binding free energies of −74.87 ± 4.94 kilocalories per mole for AKT1 with isoferulic acid, −74.81 ± 5.24 for PPARG with arctigenin and −74.87 ± 5.01 for TNF with trimethoxyflavone. The van der Waals and lipophilic terms contributed strongly to these modeled values, while hydrogen-bond terms were comparatively small. Because the study used a single trajectory per complex without independent replicates, these results are computational estimates under the specified conditions rather than experimentally observed binding energies or measurements of biological activity.

The study’s central result is a prioritization result: three phytochemicals from Guduchyadi Yoga formed computationally persistent complexes with proteins embedded in pathways associated with mild cognitive impairment and broader neurodegeneration. The work combines chemical profiling with network pharmacology, electronic-structure calculations, docking and long-duration molecular dynamics, creating mechanistic hypotheses for further testing. Important gaps remain. The researchers did not perform retrospective redocking or ligand-pose RMSD validation, and the exact receptor-grid settings could not be verified from the available records. The formulation was not tested in people with MCI, and the study did not show changes in symptoms, cognition or disease progression, nor did it demonstrate that any compound modulated its proposed target in a biological system. The findings therefore identify compounds and protein interactions for biochemical, animal and appropriately designed clinical evaluation, rather than establish a treatment effect or support clinical recommendations.

Subject of Research: Computational profiling of Guduchyadi Yoga phytochemicals and their modeled interactions with MCI-related proteins

Article Title: Chemical characterization and computational validation of Guduchyadi Yoga in mild cognitive impairment: UHPLC-HRMS, network pharmacology, docking, DFT, dynamics, and post dynamics analysis.

Article References: Yadav, P., Badal, R., Jayaraman, A., Venkatachalapathy, R., Ghildiyal, S., Rai, S., Kumar, R. C. S., Bhide, B., Sherkhane, R., & Nesari, T. (2026). Chemical characterization and computational validation of Guduchyadi Yoga in mild cognitive impairment: UHPLC-HRMS, network pharmacology, docking, DFT, dynamics, and post dynamics analysis.. Results in Chemistry, 31, Article 103983. https://doi.org/10.1016/j.rechem.2026.103983

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103983

Keywords: Guduchyadi Yoga, mild cognitive impairment, UHPLC-HRMS, network pharmacology, molecular docking, molecular dynamics, AKT1, PPARG, TNF, Ayurvedic formulation, Chemical, characterization

Carboplatin produced dose- and time-dependent cytotoxicity in the cells, with an IC₅₀ of approximately 17 µM after 48 hours. These findings offer a mechanistic model for an established anticancer drug, but the reported evidence does not establish clinical benefit in patients. Melanoma is described in the study as an aggressive malignancy with high metastatic potential and frequent resistance to standard therapies.

The authors aimed to identify molecular markers associated with melanoma progression and clarify how clinically used agents might counteract tumor-specific dysregulation. Rather than evaluating one gene or compound in isolation, the study integrated comparative gene-expression profiling with network analysis and laboratory experiments. The three analyzed datasets were processed comparatively to determine which differentially expressed genes were shared, producing a set of 194 overlapping genes.

Those genes were enriched in pathways central to tumor progression, although the supplied abstract does not identify the individual pathways or the statistical thresholds used to select them. The researchers constructed a protein–protein interaction network from the overlapping genes and used the Maximal Clique Centrality algorithm to prioritize hub genes occupying important network positions. This step was intended to identify regulatory nodes relevant to melanoma biology rather than simply rank genes by expression magnitude.

In parallel, DGIdb analysis identified carboplatin as a multi-target compound associated with CDKN1A, BRCA1, PTEN and AKT1. The analysis does not by itself show that the drug acts directly on all four targets in human tumors. Experimental testing focused on B16F0 melanoma cells.

Exposure to carboplatin caused cytotoxicity that increased with both dose and exposure time, and the reported half-maximal inhibitory concentration was approximately 17 µM at 48 hours. Reverse-transcription quantitative PCR measured increased expression of CDKN1A, BRCA1 and PTEN alongside reduced expression of AKT1. The authors interpret this pattern as evidence consistent with activation of DNA-damage-response pathways and reinforcement of tumor-suppressive signaling.

The study’s main contribution is a combined computational and cell-based framework for investigating an established anticancer drug through several transcriptomically relevant targets. The shared-gene analysis, interaction network, hub prioritization and DGIdb matching provide a testable model, while the B16F0 experiments show that carboplatin can alter the expression of the selected genes under laboratory conditions. The reported results do not provide evidence that the expression changes predict survival, recurrence or treatment response in people, nor do they establish that CDKN1A, BRCA1, PTEN or AKT1 can guide clinical selection of carboplatin.

Instead, the work identifies mechanistic associations and target-specific responses that can inform further biomarker and translational research. Its conclusions should remain bounded by the analyzed datasets and the experimental cell model, because the supplied evidence does not report patient outcomes or establish clinical efficacy for the proposed biomarker strategy.

Subject of Research: Computational and cell-based analysis of carboplatin-associated molecular targets in melanoma

Article Title: Integrative transcriptomic and network analysis elucidates the multi-target molecular mechanisms of carboplatin in melanoma

Article References: Shahriarizade, M., Ahmadi, S. M., & Firouzjaei, A. A. (2026). Integrative transcriptomic and network analysis elucidates the multi-target molecular mechanisms of carboplatin in melanoma. Medical Oncology, 43(11), Article 349. https://doi.org/10.1007/s12032-026-03460-x

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03460-x

Keywords: melanoma, carboplatin, transcriptomics, network analysis, drug-gene interactions, B16F0 cells, DNA damage response, biomarker discovery, CDKN1A, BRCA1, PTEN, AKT1

The supplied study abstract does not state the sample size, participant demographics, effect size, allelic frequencies or replication results, so the magnitude and breadth of the association cannot be assessed from the available evidence. It also does not report whether the association extended to negative symptoms or to outcomes beyond the six-week treatment period. PPP2R2B encodes a regulatory subunit of protein phosphatase 2A, or PP2A, and interacts with the dopamine D2 receptor, encoded by DRD2 .

Activity of the D2 receptor is thought to be associated with positive symptoms of schizophrenia. In the study’s gene-interaction analysis, the regulatory effect attributed to PPP2R2B appeared more pronounced in genotype groups characterized by higher DRD2 activity. Together with the study’s examination of dopaminergic synaptic signaling, the authors proposed that PP2A/PPP2R2B could serve as a mediator within a DRD2–PP2A/PPP2R2B–AKT1 signaling pathway.

In that model, PPP2R2B may participate in the modulation of dopamine signaling during aripiprazole treatment. The findings provide evidence that rs2125443 is associated with positive-symptom improvement in the six-week aripiprazole study population. They do not establish rs2125443 as a clinically actionable biomarker, and the abstract provides no basis for using it to guide treatment selection.

More broadly, the study connects a measured clinical pattern—reduction in positive symptoms on PANSS—with a gene that interacts with a dopamine-signaling receptor, while leaving the precise causal and clinical significance of the association unresolved.

Subject of Research: Genetic association with positive-symptom improvement during six weeks of aripiprazole treatment in schizophrenia

Article Title: Genome-wide association study identifies PPP2R2B as a modifier of positive symptom improvement in schizophrenia patients treated with aripiprazole

Article References: Wang, X., Lu, Z., Zhang, Y., Sun, Y., Lu, T., Yan, H., & Yue, W. (2026). Genome-wide association study identifies PPP2R2B as a modifier of positive symptom improvement in schizophrenia patients treated with aripiprazole. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08765-9

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08765-9

Keywords: schizophrenia, aripiprazole, PPP2R2B, rs2125443, genome-wide association study, positive symptoms, PANSS, dopamine D2 receptor, PP2A, AKT1, Genome-wide, association

AKT1 is a serine-threonine protein kinase that sits at the heart of one of the most heavily studied signaling networks in cancer biology: the PI3K/AKT/mTOR pathway. This pathway governs how cells respond to growth signals and shifting metabolic conditions, and when it becomes abnormally activated, it can drive uncontrolled cell proliferation, survival, altered metabolism, and resistance to therapy. Because of this central role, AKT1 has long been considered an attractive target for anticancer drugs, yet developing inhibitors that are both potent and safe has proven challenging. Understanding how AKT1 behaves differently across tumor types is therefore a critical step toward identifying biomarkers and therapeutic opportunities that are context-specific rather than universal.

To build that context, the researchers mined data from The Cancer Genome Atlas, covering 33 cancer types, and integrated information from multiple databases on gene expression, genetic alterations, DNA methylation, patient survival, immune-cell infiltration, and drug sensitivity. This multi-layered approach allowed them to examine both the shared functions of AKT1 and the ways its biological significance diverges across malignancies. The analysis revealed substantial variation in AKT1 expression between cancer types. Increased expression was observed in several malignancies, including breast, stomach, and endometrial cancers, while other tumor types displayed different patterns. Notably, AKT1 was also widely expressed in normal tissues, reflecting its essential role in cellular functions beyond cancer, a finding that underscores the difficulty of targeting it without collateral effects.

Survival analyses added further nuance. Higher AKT1 expression was associated with poorer overall and disease-free survival in liver hepatocellular carcinoma, lung adenocarcinoma, and breast cancer. In kidney renal clear cell carcinoma, however, the opposite pattern emerged, with higher expression linked to better outcomes. This variability means AKT1 expression cannot be interpreted as a universal prognostic indicator; its clinical meaning depends strongly on the biological context of each tumor. The researchers also probed the genetic and epigenetic mechanisms behind AKT1 dysregulation. Genomic profiling identified alterations in functionally important regions of the protein, including recurrent missense mutations, while DNA methylation analysis revealed reduced AKT1 promoter methylation in several cancers, including breast, kidney, liver, and lung malignancies, suggesting that both genetic and epigenetic changes may contribute to abnormal regulation of the gene.

The study then widened its lens to the tumor microenvironment. Single-cell expression data showed that AKT1 was present not only in malignant cells but also in immune and stromal populations, including macrophages, fibroblasts, and endothelial cells. Its expression was also associated with tumor mutational burden and microsatellite instability in a cancer-dependent manner. These associations may be relevant to tumor biology and to how patients respond to immunotherapy and other treatments, although the authors caution that their clinical significance remains to be established. Taken together, the pan-cancer profiling painted a picture of AKT1 as a versatile but context-dependent player in cancer, one whose usefulness as a biomarker or drug target varies considerably from one malignancy to another.

With this biological groundwork in place, the team turned to therapeutic possibilities, screening naturally occurring compounds derived from buckwheat. An initial collection of 97 phytochemicals was refined to 52 candidates suitable for computational screening against the AKT1 protein. Molecular docking was used to predict how these compounds might fit within AKT1’s binding region and to estimate the strength of their interactions. Among the screened compounds, fagopyrine showed the strongest predicted binding affinity, with a docking score of −15.45 kcal/mol. The computational analysis identified several hydrogen-bonding and hydrophobic interactions between fagopyrine and amino acid residues within the AKT1 binding pocket. Other buckwheat compounds, including quercetin, keracyanin, castasterone, and α-amyrin, also showed favorable predicted interactions, although their docking scores were less favorable than that of fagopyrine.

To test whether the predicted AKT1–fagopyrine complex would hold together under realistic physical conditions, the researchers performed molecular dynamics simulations over 100 nanoseconds. Throughout the simulation, the complex maintained a relatively stable structure, supported by analyses of molecular movement, protein flexibility, and hydrogen-bond interactions. Density functional theory calculations added a further layer of evidence about the compound’s electronic properties: the researchers observed relatively small changes in fagopyrine’s electronic structure during the simulation, alongside an increased energy gap between its highest occupied and lowest unoccupied molecular orbitals, which they interpreted as indicating favorable electronic stability within the modeled protein–ligand complex. These results strengthened the computational case that fagopyrine can engage AKT1, although the authors emphasize that simulation stability does not establish actual binding affinity or inhibition in living systems.

Important pharmacological caveats temper the enthusiasm. Predicted absorption and safety profiles revealed that fagopyrine shows only moderate gastrointestinal absorption and violates several commonly used drug-likeness criteria, including relatively high molecular weight and lipophilicity. Its known photosensitizing properties raise additional safety concerns, and a computational toxicity assessment flagged potential carcinogenicity. As the authors put it, some of the predicted drug-likeness restrictions and the reported phototoxicity of native fagopyrine suggest that it should be regarded as a promising lead scaffold rather than a clinically applicable drug candidate. In practical terms, this means chemists would need to modify the fagopyrine structure substantially, improving its pharmacological properties and reducing potential toxicity, before any related molecule could be considered for therapeutic development.

The study’s limitations are equally clear. Its conclusions rest on publicly available cancer datasets and computational modeling, without direct biochemical assays or cancer cell-line experiments confirming that fagopyrine inhibits AKT1. Docking scores and simulation stability cannot establish therapeutic efficacy, and predicted absorption or toxicity values cannot replace experimental safety assessments. Future investigations will need to test whether fagopyrine or optimized derivatives directly bind to and inhibit AKT1, affect downstream PI3K/AKT/mTOR signaling, and alter cancer-cell proliferation or survival, with additional pharmacokinetic, toxicity, and animal studies required before clinical development could even be contemplated. What the study does deliver is an integrated view of AKT1 across multiple cancer types and a computationally prioritized compound for further structure-based drug-design research, illustrating how pan-cancer molecular profiling and molecular modeling can work together to generate testable hypotheses in the ongoing search for new AKT1-targeting cancer therapies.

Subject of Research: Pan-cancer analysis of AKT1 and computational identification of the buckwheat-derived compound fagopyrine as a potential AKT1 drug-design candidate

Article Title: Pan-cancer analysis identifies buckwheat-derived compound as potential AKT1 drug-design candidate

Article References: Pan-cancer analysis identifies buckwheat-derived compound as potential AKT1 drug-design candidate. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: AKT1, pan-cancer, fagopyrine, buckwheat, molecular docking, molecular dynamics, PI3K/AKT/mTOR, drug design, Oncotarget, TCGA, phytochemicals, cancer biomarkers

The clinical reputation of ZPG as an antitussive, expectorant, and anti-asthmatic remedy preceded the study, but its precise active constituents and mechanism of action had never been fully resolved. That gap is a familiar one in traditional Chinese medicine research: herbal formulas contain dozens or hundreds of chemical compounds, many of which may contribute modestly to a therapeutic effect, making it difficult to isolate which molecules matter most and which biological pathways they engage. The research team set out to close that gap by pairing wet-lab pharmacology with bioinformatic target prediction, a strategy increasingly used to translate centuries-old formulas into modern mechanistic language.

The experimental foundation of the study rested on well-established animal and cellular models. To test the cough-suppressing and phlegm-clearing properties of the granules directly, the researchers used an ammonia water-induced cough model in mice alongside a tracheal phenol red excretion assay, a classic method for measuring how effectively a treatment promotes the clearance of respiratory secretions. ZPG performed prominently in both assays, demonstrating significant antitussive and expectorant activity. These results confirmed that the formula’s clinical effects were reproducible under controlled laboratory conditions before any mechanistic work began.

With efficacy established, the team turned to inflammation, the central pathological driver of bronchitis. They established lung inflammatory injury models both in vivo and in vitro using lipopolysaccharide, or LPS, a bacterial endotoxin that reliably triggers a robust inflammatory response in lung tissue and in cultured cells. After treating the models with ZPG, the researchers measured inflammatory factor levels using enzyme-linked immunosorbent assay, or ELISA, across three biological compartments: cell culture supernatants, serum samples, and bronchoalveolar lavage fluid, the latter being the fluid recovered from washing the airways of the experimental animals. Across all three, ZPG treatment significantly reduced the levels of inflammatory factors, indicating that the formula dampens the inflammatory cascade systemically as well as locally in the lung.

To identify which of the formula’s many chemical constituents were driving these effects, the researchers applied network pharmacology, a discipline that treats drugs and diseases as interacting networks rather than single molecule-single target relationships. Components of ZPG were screened according to two standard filters: oral bioavailability, which estimates how much of a compound survives digestion and enters the bloodstream, and drug-likeness, a composite measure of whether a molecule has the structural and physicochemical properties typical of successful drugs. Component targets were retrieved from the Symmap database, while disease targets associated with bronchitis symptoms were pulled from the GenCLiP3 database. The intersection of these two target sets formed the computational hypothesis space for the rest of the study.

Using STRING and Cytoscape software, the team constructed a Chinese medicine-component-target interaction map, revealing which herbal ingredients connected to which human proteins. Gene Ontology and KEGG pathway enrichment analyses were then performed on the key targets to identify the biological processes and signaling pathways most heavily represented. The analysis showed that ZPG exerts its antitussive and antiasthmatic functions mainly through targets such as ESR1, the estrogen receptor; DPP4, an enzyme involved in immune regulation; and MAPK14, a central kinase in stress and inflammatory signaling. Its expectorant and antiasthmatic functions were linked to targets including PPARG, a nuclear receptor that modulates inflammation; CASP3, a key executioner of programmed cell death; and INS, the insulin gene product. The full triad of antitussive, antiasthmatic, and expectorant effects converged on targets such as PTGS2, the cyclooxygenase enzyme better known as COX-2; AKT1, a hub kinase in cell survival signaling; and TNF, tumor necrosis factor, one of the most potent pro-inflammatory cytokines in the body.

The component-level analysis produced a shortlist of star molecules. Epigallocatechin gallate, or EGCG, the abundant catechin found in green tea; quercetin, a widely distributed plant flavonoid; kaempferol, another common dietary flavonoid; and beta-sitosterol, a plant sterol, emerged as the key components likely responsible for the formula’s comprehensive effects in relieving cough, reducing phlegm, and easing asthma. That several of these compounds are well-characterized polyphenols with documented anti-inflammatory activity lends biological plausibility to the network predictions, and it suggests that the therapeutic power of ZPG may derive less from exotic rare compounds and more from high concentrations of potent common phytochemicals acting in concert.

To test whether the predicted component-target interactions were physically plausible, the researchers performed molecular docking using AutoDockTools and PyMOL 2.6. Docking computationally fits a small molecule into the three-dimensional binding pocket of a protein and scores the strength of the predicted interaction. The results demonstrated strong binding between the key components, quercetin, EGCG, and kaempferol, and the key target proteins PTGS2, AKT1, and TNF. In other words, the flavonoids identified by network analysis are structurally capable of engaging the very proteins that sit at the center of the inflammatory and survival pathways implicated in bronchitis, providing a computational bridge between chemistry and pharmacology.

The enrichment analyses tied the whole picture together at the pathway level. GO and KEGG analyses identified numerous target genes and signaling pathways closely related to inflammatory responses, with the HIF-1 pathway, which governs cellular responses to low oxygen and is activated in inflamed airway tissue; the IL-17 pathway, a hallmark of neutrophil-driven airway inflammation; and the JAK-STAT pathway, a canonical cytokine signaling route, standing out as the routes through which ZPG’s key components ultimately alleviate bronchitis symptoms. Modulation of these three pathways by compounds targeting PTGS2, AKT1, and TNF offers a coherent mechanistic account of how a single herbal formula can simultaneously reduce inflammatory signaling, promote mucus clearance, and suppress the cough reflex.

The study, received in April 2026 and published open access on 8 October 2026, represents a methodological template as much as a single result: validate efficacy in animals, quantify inflammation in vivo and in vitro, then use network pharmacology and docking to explain the mechanism. The authors, led by corresponding author Wendong Li of the Beijing Institute for Drug Control, declare no competing interests. For a field often criticized for offering traditional remedies without mechanistic justification, the work shows how modern computational tools can dissect a multi-component formula into its active ingredients and target pathways, potentially guiding more precise clinical use of ZPG and informing the design of new combination therapies for inflammatory airway disease.

Subject of Research: Mechanism of Zhike Pipa Granules in treating bronchitis via network pharmacology, molecular docking, and experimental validation

Article Title: Exploring the effects and mechanisms of zike pipa granules in treating bronchitis based on network pharmacology, molecular docking and experimental validation

Article References: Qu, S., Zhou, J., Gao, Y., Li, F., Li, Z., Chen, S., Cao, C., & Li, W. (2026). Exploring the effects and mechanisms of zike pipa granules in treating bronchitis based on network pharmacology, molecular docking and experimental validation. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05609-7

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05609-7

Keywords: Zhike Pipa Granules, bronchitis, network pharmacology, molecular docking, quercetin, EGCG, kaempferol, PTGS2, AKT1, TNF, traditional Chinese medicine, inflammation

The idea behind the study is theranostics, a portmanteau of therapy and diagnostics that has become one of the most exciting frontiers in oncology. A theranostic agent combines a targeting molecule with a radioactive payload that can either emit gamma rays for imaging or beta particles for destroying tumor cells. Technetium-99m, with its 140 keV gamma emission and short six-hour half-life, is the workhorse of single-photon emission computed tomography and delivers a minimal radiation burden to patients. Rhenium-186 and rhenium-188, by contrast, emit beta particles that can kill cancer cells, making them therapeutic counterparts. Because technetium and rhenium share nearly identical electronic configurations, they form closely related coordination complexes, which is precisely what makes the pair attractive for matched diagnostic and therapeutic agents built from the same ligand.

Hesperidin is an appealing ligand for this purpose. Abundant in citrus fruits, it carries multiple hydroxyl and phenolic groups that can chelate metal ions effectively, and it has already shown cytotoxic effects in various cancer models through modulation of apoptosis and suppression of cell proliferation. Earlier experimental work showed that flavonoids such as quercetin and genistein can be labeled with technetium with radiochemical purities above 90 percent, reinforcing the idea that polyphenolic scaffolds are well suited to radiometal coordination. The research team, led by Taufik Muhammad Fakih and Muchtaridi Muchtaridi, set out to determine computationally whether hesperidin could serve the same dual role for both technetium and rhenium.

The first stage of the investigation relied on density functional theory. The team built three-dimensional models of both metal-hesperidin complexes, optimized their geometries using the B3LYP hybrid functional, and treated the heavy metal centers with the LANL2DZ effective core potential to capture relativistic effects. Frequency calculations confirmed that each optimized structure represented a true energy minimum with no imaginary frequencies. The frontier molecular orbital analysis revealed striking similarity between the two complexes: the HOMO-LUMO energy gap was 0.08848 Hartree for the rhenium complex and 0.08689 Hartree for the technetium complex, indicating nearly identical chemical reactivity. In both cases, the frontier orbitals remained localized on the aromatic rings and oxygen-containing substituents of hesperidin, showing that metal coordination does not disrupt the ligand’s intrinsic electronic distribution or its pharmacophoric structure.

Subtle differences did emerge from the global reactivity descriptors. The technetium complex showed a slightly higher ionization potential, electron affinity, electronegativity, and electrophilicity index, suggesting a marginally stronger tendency to accept electron density. The rhenium complex, meanwhile, exhibited a higher dipole moment of 7.02 Debye compared with 6.52 Debye for technetium, and greater polarizability, hinting at stronger electrostatic interactions in polar environments. A control calculation using the HSEH1PBE functional on the technetium complex produced broadly consistent trends, supporting the internal reliability of the electronic-structure analysis while underscoring that all of these values remain theoretical predictions.

With the electronic groundwork laid, the researchers turned to molecular docking against five breast cancer-related proteins: the estrogen receptor alpha, HER2, AKT1, EGFR, and PIK3CA. After validating the docking protocol by re-docking each receptor’s co-crystallized ligand, with root-mean-square deviations well below 2.0 angstroms for four of the five targets, they ran 100 independent docking simulations per receptor-ligand pair. The results pointed decisively toward kinase targets. Rhenium-hesperidin bound AKT1 with a binding energy of minus 7.49 kcal/mol, corresponding to a micromolar inhibition constant of 3.21 micromolar, the strongest interaction in the entire panel, supported by an extensive hydrogen-bonding network involving residues such as Asn54, Gln59, and Thr211, and hydrophobic contacts with Trp80, Val270, and Leu264. EGFR followed at minus 5.62 kcal/mol, while the hormone receptor ERα and HER2 showed only weak, millimolar-range binding.

The technetium complex told a complementary story. It also favored AKT1, but with a weaker binding energy of minus 5.17 kcal/mol and an inhibition constant of 163.59 micromolar, and its interactions across the panel were generally less potent and less persistent than those of the rhenium analogue. The researchers interpret this asymmetry as functionally meaningful: the stronger, more stable binding of rhenium-hesperidin suits a therapeutic role, while the weaker, more transient engagement of technetium-hesperidin fits the requirements of an imaging agent, which must bind briefly, reveal its location, and clear away.

To test whether these static snapshots would hold up in a dynamic, water-filled environment, the team ran 100-nanosecond molecular dynamics simulations of the two complexes bound to AKT1 and EGFR, using the AMBER99SB-ILDN force field and custom parameters for the metal centers. Both complexes remained stably accommodated in the binding pockets, with acceptable radius of gyration and solvent-accessible surface area profiles. Hydrogen-bond occupancy analysis was particularly revealing: rhenium-hesperidin achieved a total hydrogen-bond occupancy of 407.72 percent against EGFR, far exceeding the 9.11 percent of the native ligand, with persistent contacts at Met793, Lys745, Ser720, and Thr854, residues central to EGFR kinase activity. Technetium-hesperidin also outperformed the native ligand but with lower overall occupancy, again consistent with more reversible binding.

The binding free-energy estimates from MM-PBSA calculations added a final, and deliberately cautious, layer of nuance. For AKT1, the technetium complex produced the most negative mean binding free energy at minus 282.81 kJ/mol, driven by strong van der Waals contributions, compared with minus 220.48 kJ/mol for rhenium. For EGFR, the picture reversed: rhenium-hesperidin averaged minus 47.73 kJ/mol while the technetium complex averaged a slightly positive 20.15 kJ/mol. The authors are careful to stress that these single-trajectory estimates carry large standard deviations, particularly for EGFR, and should be read as comparative trends rather than a definitive ranking. The apparent discrepancy between docking and MM-PBSA reflects the different theoretical foundations of the two methods, one evaluating static poses with empirical scoring and the other incorporating flexibility and solvation from dynamic trajectories.

The study’s limitations are candidly acknowledged: no experimental validation has yet been performed, the PIK3CA docking failed its re-docking criterion, and each molecular dynamics system was simulated only once. Even so, the work lays a credible theoretical foundation for a genuinely elegant concept, a single citrus flavonoid that could carry a gamma-emitting technetium label into the clinic for imaging breast tumors and a beta-emitting rhenium label for therapy, preferentially engaging the AKT1 and EGFR kinases that drive cancer proliferation and survival. Turning that computational promise into a bedside radiopharmaceutical will require radiolabeling experiments, stability and biodistribution studies, and ultimately clinical testing, but the molecular blueprint now exists, and it smells faintly of oranges.

Subject of Research: Computational evaluation of technetium- and rhenium-labeled hesperidin complexes as radiotheranostic agents for breast cancer

Article Title: Theoretical evaluation of technetium-to-rhenium substitution in hesperidin complexes for breast cancer theranostic potential

Article References: Fakih, T. M., Novitasari, D., Syaifudin, M., & Muchtaridi, M. (2026). Theoretical evaluation of technetium-to-rhenium substitution in hesperidin complexes for breast cancer theranostic potential. Heliyon, 12(15), Article e45458. https://doi.org/10.1016/j.heliyon.2026.e45458

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45458

Keywords: hesperidin, technetium-99m, rhenium-188, theranostics, breast cancer, molecular docking, molecular dynamics, DFT, AKT1, EGFR, radiopharmaceuticals, flavonoids

The research, led by Bishwa Raj Pokharel and senior author Baohong Zhang of East Carolina University, together with colleagues at Henan Institute of Science and Technology in China and Arak University in Iran, integrated three layers of analysis: visible growth traits, biochemical stress markers, and gene expression dynamics. This combined approach matters because plants rarely respond to nanoparticles in a single, simple way. A seedling may look healthy on the surface while its molecular machinery is quietly scrambling to cope, or it may appear stunted while its stress-response genes are firing on all cylinders. By measuring all three dimensions simultaneously, the team could trace how physical damage, oxidative stress, and genetic adaptation feed into one another.

The headline discovery is a distinctly nonlinear dose-response relationship. At higher concentrations, aluminum oxide nanoparticles significantly inhibited root length and reduced the number of leaves the plants produced, classic signs of phytotoxicity. Roots are typically the first line of contact for soil-borne nanoparticles, and their sensitivity is well documented across other metal oxide particles. But at lower concentrations, the story flipped: the nanoparticles promoted leaf length and increased shoot fresh weight. This biphasic pattern is a textbook example of hormesis, the biological phenomenon in which a stressor is beneficial at low doses and harmful at high doses. Hormesis has been observed with other nanoparticles in plant tissue culture and crop systems, but documenting it in a biofuel crop like camelina carries practical weight for anyone hoping to deploy nanotechnology in agriculture safely.

Behind the visible growth changes, the researchers found clear biochemical evidence of oxidative stress at elevated nanoparticle concentrations. Levels of hydrogen peroxide, a reactive oxygen species, rose alongside malondialdehyde, a well-established marker of lipid peroxidation that indicates damage to cellular membranes. Reactive oxygen species are a double-edged sword in plant biology. At controlled levels they act as signaling molecules that coordinate development and stress responses, but when their production outpaces the plant’s antioxidant defenses, they attack proteins, DNA, and lipids. The accumulation of both hydrogen peroxide and malondialdehyde in the treated camelina plants suggests that high nanoparticle doses pushed the balance decisively toward damage, overwhelming the antioxidant systems that normally keep these molecules in check.

Perhaps the most revealing part of the study came from the gene expression analysis. The team observed significant upregulation of stress response genes, including AECC1 and AKT1, indicating that the plants were not passive victims but were actively mounting adaptive molecular responses. AKT1 is particularly interesting: it encodes a potassium channel involved in ion homeostasis, and its activation under nanoparticle stress hints that camelina may be trying to rebalance its internal mineral economy in response to aluminum exposure. Aluminum toxicity is a notorious problem in acidic soils worldwide, where the metal ion disrupts root cell elongation and nutrient uptake, and plants have evolved a repertoire of genes to cope with it. The fact that nanoparticle exposure appears to recruit similar molecular pathways suggests a partial overlap between the biology of aluminum ion toxicity and the biology of aluminum oxide nanoparticles, even though the two forms of the metal behave very differently in the environment.

That distinction is important. Unlike soluble aluminum ions, aluminum oxide nanoparticles are solid particles whose effects depend on size, surface chemistry, and their tendency to aggregate. Earlier work by the same research group, including a systematic review of aluminum nanoparticle uptake and transport in plants published in Environmental Pollution, highlighted how these particles can adhere to root surfaces, alter cell wall structure, and in some cases enter plant tissues. Other studies have shown that nanoparticle exposure can trigger genotoxic effects and alter microRNA expression, as demonstrated in tobacco by the Zhang laboratory more than a decade ago. The new camelina study builds on this foundation by tying together the phenotypic, biochemical, and transcriptomic threads in a single crop system, offering a more complete picture than any one measurement could provide.

The choice of camelina as the study organism is strategic. Camelina sativa is a member of the Brassicaceae family with a short growing season, low input requirements, and remarkable tolerance for marginal lands where food crops struggle. Its seed oil is rich in omega-3 fatty acids and is being developed for biodiesel, sustainable aviation fuel, and industrial oleochemicals. Recent biotechnological advances have positioned camelina as a lipid engineering platform, and researchers are actively mapping its genome and identifying quantitative trait loci for adaptive traits. If nanoparticles are increasingly present in agricultural soils, understanding how they affect a crop that may be grown on millions of hectares of marginal land is not an academic luxury; it is a prerequisite for responsible deployment of nanotechnology in bioenergy agriculture.

The study’s implications cut in two directions. On the cautionary side, the inhibition of root growth and leaf production at high nanoparticle concentrations, combined with elevated oxidative damage markers, signals genuine risk if aluminum oxide nanoparticles accumulate in soils at sufficient levels. Environmental fate studies have shown that engineered nanoparticles can be transported through soil columns and surface waters, meaning agricultural exposure is plausible rather than hypothetical. On the constructive side, the growth promotion observed at low doses, together with the activation of adaptive stress genes, suggests that carefully calibrated nanoparticle applications could potentially be harnessed, much as zinc oxide nanoparticles have been explored as nanofertilizers that improve nutrient uptake and stress tolerance in crops like rice and tomato. The key variable is dose, and the nonlinear nature of the response means that the margin between benefit and harm may be narrow.

The researchers emphasize that their findings contribute to the broader understanding of nanoparticle phytotoxicity and support the development of safer, more sustainable agricultural applications of nanotechnology. That framing reflects a growing consensus in the field: nanoparticles are neither inherently good nor inherently bad for plants, but their effects emerge from an intricate interplay of dose, particle properties, plant species, and environmental context. Studies in barley, lettuce, fenugreek, tomato, and Arabidopsis have all documented species-specific responses to aluminum oxide nanoparticles, and the camelina data now add a biofuel crop to that roster. The upregulation of genes like AECC1 and AKT1 also provides molecular markers that future studies can use to screen for nanoparticle stress in breeding programs or to engineer more tolerant crop varieties.

As engineered nanomaterials continue to saturate industrial supply chains, the boundary between technological benefit and environmental liability will be drawn in places like root tips and chloroplast membranes, at concentrations measured in parts per million. This study of camelina offers a template for how to find that boundary: measure the visible phenotype, quantify the biochemical damage, and read the plant’s own genetic testimony. The nonlinear dance between stimulation and inhibition that the researchers documented is a reminder that in nanotoxicology, as in much of biology, the dose truly makes the poison, and sometimes, at just the right concentration, it makes a slightly better plant as well.

Subject of Research: Effects of aluminum oxide nanoparticles on growth, oxidative stress, and gene expression in the biofuel crop Camelina sativa

Article Title: Integrated analysis of aluminum oxide nanoparticle effects on Camelina sativa performance and molecular signaling

Article References: Pokharel, B. R., Prakash, A., Li, L., Sheri, V., Kohtz, D., Hatami, M., & Zhang, B. (2026). Integrated analysis of aluminum oxide nanoparticle effects on Camelina sativa performance and molecular signaling. 3 Biotech, 16(10), Article 432. https://doi.org/10.1007/s13205-026-05045-x

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05045-x

Keywords: aluminum oxide nanoparticles, Camelina sativa, phytotoxicity, oxidative stress, gene expression, hormesis, biofuel crops, reactive oxygen species, nanotechnology in agriculture, plant stress response, AKT1, dose-response

The investigation began with a sweeping chemical census. Drawing on the IMPPAT 2.0 database, a manually curated repository built from more than 100 traditional Indian medicinal texts and over 7,000 peer-reviewed publications, the researcher retrieved 123 phytochemicals associated with Camellia sinensis. Canonical SMILES structures were cross-referenced through PubChem, and each compound was then pushed through a battery of in silico filters: admetSAR 3.0, SwissADME, the artificial intelligence-driven Deep-PK platform, and the graph-based predictor pkCSM. The gauntlet evaluated molecular weight, lipophilicity, hydrogen bonding capacity, topological polar surface area, gastrointestinal absorption, blood-brain barrier permeation, cytochrome P450 inhibition, clearance, mutagenicity, hepatotoxicity, and acute oral toxicity.

Only 14 compounds survived the full screening cascade, and their identities are telling. The list includes familiar catechins such as epicatechin and cianidanol, phenolic acids like caffeic acid and gallic acid, vitamins and cofactors including ascorbic acid and pantothenic acid, and a striking contingent of brassinosteroid-related sterols: typhasterol, teasterone, brassinolide, and castasterone, alongside the triterpenoid saponin theasapogenol B and the sapogenin A1-barrigenol. Notably, several high-profile tea polyphenols, including theasinensins and heavily galloylated derivatives, failed Lipinski’s rule of five because their sheer molecular size and polar surface area would sabotage oral bioavailability. The survivors, by contrast, showed high predicted gastrointestinal absorption, minimal interference with major CYP450 drug-metabolizing enzymes, and largely non-mutagenic, non-hepatotoxic profiles.

With the shortlist established, the study turned to target prediction. SwissTargetPrediction, a reverse-screening engine built on chemical similarity principles, assigned up to 100 putative human protein targets to each of the 14 phytochemicals, generating 1,400 raw predictions that collapsed to 262 unique proteins after deduplication. These were fed into the STRING database to construct a protein-protein interaction network of 260 nodes and 2,504 edges, with an average node degree of 19.3 and a PPI enrichment p-value below 1.0 × 10⁻¹⁶, confirming that the connectivity reflects genuine biology rather than statistical noise. Applying a stringent combined-score threshold above 0.9 retained 488 high-confidence interactions for downstream analysis.

Clustering algorithms then carved the network into eight functional modules, each a dense island of cooperating proteins. The top-scoring module, with an MCODE score of 10.824, was dominated by the PI3K/AKT and receptor tyrosine kinase machinery, including PIK3CA, AKT1 through AKT3, EGFR, ERBB2, JAK1 through JAK3, and IGF1R. Other modules captured cell cycle regulators such as CDK1, AURKA, and PLK1; GABA receptor subunits tied to neurotransmission; MAPK stress-signaling proteins; a neurodegeneration-and-apoptosis cluster featuring PSEN1, PSEN2, GSK3B, and HDAC1; cell cycle checkpoint proteins; matrix metalloproteinases involved in tissue remodeling; and cholesterol biosynthesis enzymes including HMGCR and SQLE. The breadth of these modules hints at why tea has been linked to such a bewildering variety of health benefits.

To separate the true regulatory heavyweights from peripheral players, the study applied four independent centrality algorithms in the cytoHubba plugin: Degree, Betweenness, Closeness, and Maximal Clique Centrality. Only three proteins ranked among the top ten under every single method: PIK3CA, the catalytic subunit of phosphatidylinositol-3-kinase; AKT1, the master survival kinase; and ESR1, the estrogen receptor alpha. The convergence is biologically compelling. The PI3K/AKT axis governs proliferation, apoptosis, glucose metabolism, and inflammatory signaling, and its dysregulation is a hallmark of cancer, insulin resistance, and neurodegeneration, while ESR1 sits at the intersection of hormonal signaling, neuroprotection, and breast cancer biology.

Functional annotation through the DAVID platform painted the pathways these hubs inhabit. Gene Ontology analysis linked them to apoptosis, glucose metabolic processes, insulin receptor signaling, kinase activity, and PI3K signal transduction, with cellular localization concentrated in the cytosol, plasma membrane, and lamellipodia. KEGG pathway enrichment pulled in an impressive roster of disease-relevant cascades: pathways in cancer, TNF signaling, HIF-1 signaling, AMPK signaling, FoxO signaling, VEGF signaling, estrogen signaling, Toll-like receptor signaling, prolactin signaling, and thyroid hormone signaling. A phytochemical-target-pathway network then visualized how the 14 compounds converge on AKT1, ESR1, and PIK3CA, which in turn fan out into these interconnected pathways, a textbook illustration of the multitarget, multi-pathway logic that distinguishes network pharmacology from the classical one-drug-one-target paradigm.

The structural validation stage delivered the study’s most eye-catching numbers. Using AutoDock Vina through PyRx, with docking protocols verified by re-docking co-crystallized ligands to RMSD values between 1.0 and 1.2 angstroms, several tea phytochemicals outperformed their reference inhibitors. Epicatechin and cianidanol bound AKT1 at −9.8 kcal/mol, comfortably beating the reference ligand IQO at −6.9. For the estrogen receptor ESR1, typhasterol and theasapogenol B reached −8.9 kcal/mol against OHT’s −6.5. And castasterone posted −9.7 kcal/mol against PIK3CA, far surpassing the 2Q7 reference at −6.5. Interaction maps showed the compounds engaging the same catalytic residues as the native ligands: epicatechin and cianidanol contacting Thr211, Lys268, and Val270 in AKT1; epicatechin hydrogen-bonding with Asp351 and Glu353 in ESR1; and multiple compounds anchoring to Lys802, Arg992, and Leu1028 in PIK3CA.

The authors are careful to frame these findings as hypothesis-generating rather than definitive. Docking scores estimate relative interaction strength but do not substitute for measured binding affinities, the enrichment analyses relied on unadjusted p-values vulnerable to false positives, and no ligand pose superposition or molecular dynamics simulations were performed. Experimental validation in vitro and in vivo remains the essential next step. Even so, the study provides a rigorous, systems-level rationale for centuries of empirical enthusiasm about tea, pinpointing epicatechin, cianidanol, castasterone, typhasterol, and theasapogenol B as the most promising candidates and PIK3CA, AKT1, and ESR1 as the molecular crossroads where a humble cup of tea may exert its most consequential effects.

Subject of Research: Multitarget therapeutic potential of Camellia sinensis phytochemicals analyzed by network pharmacology and molecular docking

Article Title: Elucidating the multitarget therapeutic potential of Camellia sinensis (Tea) phytochemicals using network pharmacology, functional annotation, and molecular docking

Article References: Hossain, M. M. (2026). Elucidating the multitarget therapeutic potential of Camellia sinensis (Tea) phytochemicals using network pharmacology, functional annotation, and molecular docking. Discover Chemistry, 3(1), Article 541. https://doi.org/10.1007/s44371-026-01000-0

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01000-0

Keywords: Camellia sinensis, tea, network pharmacology, molecular docking, phytochemicals, PIK3CA, AKT1, ESR1, ADMET, drug discovery, cancer, molecular targets

The motivation comes from a decade of accumulating evidence on the gut–bone axis. Germ-free animals, antibiotic-treated animals, and recipients of fecal microbiota transplants all show measurable changes in bone mineral density and osteoclast activity, and Mendelian randomization studies have hinted at causal links between particular microbial taxa and osteoporosis traits. Microbial metabolites are widely viewed as the chemical messengers of this axis: short-chain fatty acids such as butyrate can rebalance regulatory and inflammatory T cell populations and even prompt bone marrow CD8-positive T cells to secrete Wnt10b, directly stimulating bone formation, while tryptophan derivatives can activate the aryl hydrocarbon receptor and shore up the intestinal barrier. What has been missing, the authors contend, is a systematic way to connect these metabolites to concrete host signaling molecules without losing track of which microbe and which substrate produced them.

To build that bridge, the team first compiled 251 gut microbiota-related metabolites and 238 human intestinal host targets from the gutMGene database, which curates literature-derived associations between microbes, their substrates, their metabolites, and human genes. Metabolite structures were retrieved from PubChem as standardized SMILES strings and submitted to two target-prediction platforms, the Similarity Ensemble Approach and SwissTargetPrediction, producing a deduplicated set of 1,518 candidate human protein targets. In parallel, osteoporosis-related genes were harvested from three disease databases, CTD, GeneCards, and OMIM, yielding 2,213 unique disease-associated targets. Intersecting the three lists produced 48 shared targets, a number that proved robust in sensitivity analyses using stricter prediction-confidence filters and higher GeneCards relevance-score cutoffs.

The 48 shared proteins were then mapped onto a protein–protein interaction network built with STRING at medium confidence, revealing 540 interactions. Five genes stood out as the most connected candidate hubs: TP53, with the highest node degree of 41, followed by IL6, AKT1, and TNF at 40 connections each, and IL1B at 39. Crucially, the authors resisted the temptation to crown a single master regulator. When they computed complementary topology measures, IL1B showed the highest betweenness centrality, while TP53 led on closeness and eigenvector centrality, and AKT1 remained highly connected without ranking first on any single metric. The team accordingly retained all five as candidate hubs for downstream analysis rather than as proven central mediators.

Functional enrichment analyses gave the shared target set a recognizable biological identity. Gene Ontology terms pointed to responses to molecules of bacterial origin, lipopolysaccharide, biotic and xenobiotic stimuli, and regulation of apoptotic signaling, alongside molecular functions involving histone deacetylase activity and MAP kinase activity. Kyoto Encyclopedia of Genes and Genomes pathway analysis highlighted Toll-like receptor, IL-17, TNF, NOD-like receptor, MAPK, and PI3K-Akt signaling, as well as osteoclast differentiation and apoptosis. The inflammatory flavor of these results fits established bone biology: TNF-alpha amplifies osteoclast precursor differentiation, IL-1beta induces stromal RANKL expression, and IL-6 promotes osteocyte-mediated osteoclast formation, while all three cytokines can suppress osteogenic markers such as RUNX2 and shift remodeling toward resorption.

The centerpiece of the study is the edge-level M-S-M-T network itself, which arranges four node layers, 64 gut microbiota, 22 substrates, 30 metabolites, and the five candidate hub targets, connected by 150 edges. Enumerating directed routes from microbe to substrate to metabolite to hub yielded 479 candidate four-layer paths, with AKT1 reachable through 225 of them, IL1B through 101, TP53 through 60, TNF through 53, and IL6 through 40. The authors are explicit that this count reflects graph-theoretical connectivity in a many-to-many network, not 479 independently validated causal chains, and that records lacking a reported substrate were retained through a single placeholder node used only for visualization. Within the network, two interpretable modules emerged. Records for Clostridium sporogenes linked the amino acid tryptophan to 3-indolepropionic acid and indole-3-lactic acid, both of which were connected to AKT1. Records for Bacteroides sp. 45 supported flavonoid branches in which quercitrin connects to quercetin and hydroxyquercitrin, and rutin to isoquercetin, with endpoints at AKT1, TNF, and IL6.

To probe the plausibility of these candidate links at the structural level, the team docked three representative metabolites, 3-indolepropionic acid, indole-3-lactic acid, and quercetin, into the AKT1 crystal structure. All three produced energetically favorable poses, with quercetin achieving the most favorable score at minus 9.6 kcal/mol, followed by indole-3-lactic acid at minus 8.0 and 3-indolepropionic acid at minus 7.8. Preliminary ADMET profiling of eleven representative metabolites showed that all satisfied the conventional Lipinski rule-of-five criteria, but the toxicity predictions were heterogeneous, with several compounds, quercetin among them, flagged for elevated hepatotoxicity or carcinogenicity-related endpoints. The researchers stress that docking scores demonstrate only qualitative structural plausibility and that physicochemical criteria designed for oral drugs should not be read as evidence of therapeutic suitability for endogenous, diet-derived molecules.

The most striking external evidence came from three independent human transcriptomic datasets that played no role in building the network. In age-matched bone marrow mesenchymal stem cells from donors with primary osteoporosis, AKT1 was strongly upregulated with a log2 fold-change of 1.59 and a genome-wide false-discovery rate of 0.0099, and TP53 was likewise significantly elevated at a log2 fold-change of 1.55 and an FDR of 0.037, with TNF showing a nominally significant increase. Yet the same five hubs showed weak or inconsistent changes in circulating monocytes from postmenopausal women with low versus high bone mineral density, and no hub reached even nominal significance in circulating B cells. Fisher-combined P values across the three datasets were significant for AKT1 and TP53 but not for the inflammatory cytokine genes, pointing to a cell-type-specific transcriptional perturbation in bone-lineage cells rather than a systemic signal detectable in peripheral blood.

The authors frame the work deliberately as hypothesis-generating rather than confirmatory. Database coverage and publication frequency can inflate the prominence of well-studied genes such as AKT1 and TP53, pathway enrichment alone does not establish osteoporosis specificity, and the transcriptomic validation was confined to steady-state mRNA in three microarray datasets. No cellular perturbation experiments, protein-level measurements, animal models, or prospective clinical samples were available, and docking was limited to a single receptor and three ligands without molecular dynamics or biochemical binding assays. The value of the framework, they argue, lies in converting a vast database-derived network into a small number of testable modules, most notably the Clostridium sporogenes–tryptophan–indole metabolite–AKT1 axis and the Bacteroides sp. 45 flavonoid module, each anchored by convergent expression evidence in the right cell type.

If those modules withstand experimental scrutiny, the implications could extend well beyond osteoporosis research. A provenance-preserving network of this kind offers a template for studying how microbial chemistry reaches any host organ, and it suggests that interventions targeting the gut, whether through diet, probiotics, or metabolite supplementation, might eventually be rationally matched to molecular targets in bone. For now, AKT1 stands as one candidate signal-integration hub among several, not the unique center of the gut–bone axis, and the pathway from a Clostridium cell in the intestinal lumen to a mesenchymal stem cell in the marrow remains a hypothesis waiting for the laboratory tests that must now follow.

Subject of Research: Computational mapping of links between gut microbiota-derived metabolites and osteoporosis through a microbiota–substrate–metabolite–target network centered on candidate hub AKT1

Article Title: A microbiota–substrate–metabolite–target network suggests AKT1-associated links between gut microbiota-derived metabolites and osteoporosis

Article References: Zeng, W., Gong, Y., Liao, Y., Xie, X., Qin, Z., Li, C., & Zhang, X. (2026). A microbiota–substrate–metabolite–target network suggests AKT1-associated links between gut microbiota-derived metabolites and osteoporosis. International Microbiology. https://doi.org/10.1007/s10123-026-00899-w

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00899-w

Keywords: gut microbiota, osteoporosis, gut–bone axis, AKT1, microbial metabolites, tryptophan metabolites, flavonoids, quercetin, molecular docking, network pharmacology, bone remodeling, transcriptomic validation

Chitosan is a cationic polysaccharide derived from chitin, the second most abundant natural polymer on Earth after cellulose and the structural backbone of crustacean exoskeletons. Chemically, chitosan consists of repeating units of D-glucosamine and N-acetyl-D-glucosamine linked by beta-(1,4) glycosidic bonds, and its native amine groups become protonated at physiological pH. This positive charge allows the polymer to interact electrostatically with negatively charged cell membranes, modulating cell adhesion, migration and proliferation. Because of these properties, chitosan has long attracted interest as a wound-dressing material that can promote tissue regeneration, stimulate fibroblast activity, accelerate hemostasis and suppress microbial infection. The single most important quality parameter is the degree of deacetylation, the proportion of deacetylated glucosamine units in the chain; a chitin sample with more than 50 percent deacetylation is generally classified as chitosan, and higher values typically improve solubility, antimicrobial performance and biological interactions.

The catch has always been how to make it. Conventional extraction subjects shrimp shell powder to concentrated sodium hydroxide at high temperatures for hours, an energy-intensive process that risks degrading the polymer backbone and inflating production costs. Alternative technologies each carry their own burdens: ultrasound can accelerate extraction but may cleave polymer chains and reduce molecular weight, enzyme-assisted routes offer selectivity at the price of costly catalysts and long processing times, and deep eutectic solvents reduce harsh chemical use but complicate solvent recovery at industrial scale. Microwave-assisted extraction promises shorter reaction times, lower electricity consumption, simpler equipment and easier scalability, because microwave radiation heats the reaction mixture directly and uniformly through dipole rotation and ionic conduction rather than through slow conduction and convection.

The research team, working with shrimp shell waste from Indonesian processing of Litopenaeus vannamei, ground and sieved the dried shells to 74 to 150 micrometers and then optimized each of the three extraction stages under microwave irradiation. Demineralization with hydrochloric acid proved to be governed mainly by acid concentration rather than microwave power: at 0.5 M HCl more than 72 percent of the calcium remained, while both 1 M and 2 M HCl achieved complete calcium removal across 400, 500 and 600 watts within just five minutes. Deproteinization with sodium hydroxide followed a similar pattern, with protein removal rising from 99.18 percent at 2 percent NaOH to a full 100 percent at 10 percent NaOH, regardless of the power level applied.

Deacetylation, the step that transforms chitin into chitosan, responded strongly to both alkali concentration and microwave power. At a fixed 600 watts, increasing NaOH from 40 to 80 weight percent pushed the degree of deacetylation toward 80 percent even in five-minute treatments, and extending the reaction to ten minutes at 600 watts and 80 percent NaOH lifted the value to nearly 85 percent. FTIR spectroscopy, using the ratio of absorbance bands at 1320 and 1420 inverse centimeters, confirmed a degree of deacetylation of 85 percent for microwave-synthesized chitosan versus 80 percent for the conventionally produced material. More striking was the yield: microwave processing converted 10 percent of the starting shell mass into final chitosan, compared with only 1.6 percent for the conventional route, a six-fold improvement in material efficiency.

Structural characterization reinforced the case for the microwave route. X-ray diffraction showed that both products were semi-crystalline, but the conventionally synthesized sample exhibited a broadened and weakened peak near 2 theta of 10 degrees, indicating loss of crystallinity, whereas the microwave product retained a well-defined crystalline peak, suggesting that rapid volumetric heating minimizes disruption of the polymer backbone. Scanning electron microscopy revealed characteristic lamellar flake morphologies with smooth surfaces and dense packing for both materials, consistent with a high density of free amino groups. At the molecular level, the researchers explain the difference through kinetics: hydroxide ions attack the electrophilic carbonyl carbon of chitin’s acetamide groups, cleaving the C–N bond and releasing acetate, and microwave-driven dipolar heating accelerates this nucleophilic attack throughout the crystalline core instead of forcing slow diffusion from a hot surface inward.

The biological evaluation focused on RAW 264.7 murine macrophage-like cells, key players in the inflammatory phase of wound repair. In MTT cytotoxicity assays, microwave-derived chitosan at concentrations from 0.1 to 10 milligrams per milliliter did not significantly reduce cell viability over 24 or 48 hours of incubation, demonstrating excellent cytocompatibility. In scratch assays, monolayers cultured on the chitosan-coated substrates showed progressive wound closure beginning around 12 hours, with the cell-free gap nearly completely closed after 48 hours. The authors attribute this activity in part to positively charged calcium ions released from the biopolymer, which may enhance cell proliferation, and to the hydrophilic character of the chitosan surface. They caution, however, that macrophage results represent only one facet of a process that also depends on fibroblasts, keratinocytes, endothelial cells and extracellular matrix remodeling, and that fibroblast and keratinocyte models plus in vivo studies are needed to confirm therapeutic efficacy.

To probe mechanism, the team performed molecular docking of chitosan malate against AKT1, a protein kinase central to the PI3K/AKT signaling pathway that drives cell proliferation, migration and angiogenesis during tissue repair. Chitosan malate showed a predicted binding affinity of minus 9.6 kilocalories per mole toward AKT1, stronger than the known AKT activator SC79 at minus 7.9, with predicted contacts at residues Thr81, Thr82 and Arg273 in the PH domain and near the kinase domain interface. The researchers stress that these are exploratory computational estimates: the study did not measure AKT1 expression or phosphorylation, so any involvement of the pathway in the observed wound-closure behavior remains a hypothesis requiring experimental validation.

The economic case may prove equally consequential. By integrating equipment power ratings over operating times, the team calculated that microwave-assisted synthesis consumed up to 94.6 percent less energy than conventional heating. A techno-economic analysis anchored to Indonesian market conditions yielded a positive net present value of approximately USD 10.73 million, an annual profitability investment of 18.62 percent, and a benefit-cost ratio of 17.72, comfortably above the feasibility threshold of unity. Sensitivity analyses varying the product selling price by plus or minus 15 percent showed that the project remained profitable even in the worst scenario, with NPV near USD 9 million and a benefit-cost ratio of 15. Taken together, the results position microwave extraction as a commercially viable, energy-efficient pathway for turning one of the seafood industry’s largest waste streams into a biomedical raw material, though the authors note that pilot-scale validation, molecular-weight characterization, in vivo testing and continuous reactor design remain the next hurdles before clinical and industrial adoption.

Subject of Research: Microwave-assisted synthesis of high-quality chitosan from shrimp shell biowaste for wound-healing applications

Article Title: Comparative study of microwave-assisted and conventional methods for the synthesis of high-quality chitosan from shrimp shell biowaste to manipulate cell growth and functions: Supported molecular docking analysis

Article References: Rahmatunnisa, C., Budi, C. S., Ilhami, F. B., Puspitarini, S., Melanie, M., Hapidin, D. A., Kuo, D.-H., Zeleke, M. A., Kurnia, I., Hastuti, L. P., Rahmah, D. M., & Gultom, N. S. (2026). Comparative study of microwave-assisted and conventional methods for the synthesis of high-quality chitosan from shrimp shell biowaste to manipulate cell growth and functions: Supported molecular docking analysis. Case Studies in Chemical and Environmental Engineering, 14, Article 101481. https://doi.org/10.1016/j.cscee.2026.101481

Image Credits: AI Generated

DOI: 10.1016/j.cscee.2026.101481

Keywords: chitosan, shrimp shell waste, microwave-assisted extraction, chitin deacetylation, wound healing, biomaterials, molecular docking, AKT1, techno-economic analysis, biocompatibility, energy efficiency, marine biowaste